Myelodysplastic syndromes
M Cazzola - New England Journal of Medicine, 2020 - Mass Medical Soc
New England Journal of Medicine, 2020•Mass Medical Soc
Myelodysplastic Syndromes MDS are clonal hematopoietic disorders involving morphologic
defects and peripheral-blood cytopenias, with a risk of progression to acute myeloid
leukemia. Except for del (5q) MDS, which is responsive to lenalidomide, these disorders are
largely managed with supportive care.
defects and peripheral-blood cytopenias, with a risk of progression to acute myeloid
leukemia. Except for del (5q) MDS, which is responsive to lenalidomide, these disorders are
largely managed with supportive care.
Myelodysplastic Syndromes
MDS are clonal hematopoietic disorders involving morphologic defects and peripheral-blood cytopenias, with a risk of progression to acute myeloid leukemia. Except for del(5q) MDS, which is responsive to lenalidomide, these disorders are largely managed with supportive care.
The New England Journal Of Medicine